Search

It is currently unknown how effective the COVID-19 vaccine is at preventing new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among the general population. The study suggests that a safe and efficient vaccination against the COVID-19 could help manage this pandemic if widely distributed. The present study aimed to investigate the effectiveness of the ChAdOx1 nCoV-19 vaccine in between vaccinated and unvaccinated cohorts. A retrospective multicenter cohort study comprised 1244 COVID-19 positive patients enrolled in this study from three different hospitals among patients who had been appropriately vaccinated or not between April and June 2021. Data were collected by face-to-face survey, and clinical investigations were obtained by observation. Descriptive statistics and the Cox proportional hazard model of survival analysis were performed in the study. Among the participants, 69% of vaccinated cohorts did not require hospitalization, and 97% successfully recovered from the infection. In respect of age, compared with unvaccinated cohorts, the vaccine effectiveness varied from 81% to 92%. The ChAdOx1 nCoV-19 vaccine was more effective among those aged 60-69 years old and reduced 92% hazard of death than the unvaccinated group [HR ratio - 0.081(.036-.179), P=0.0001]. The study found the ChAdOx1 nCoV-19 vaccine is highly effective for receivers. The COVID-19 vaccination demonstrated a significant correlation with a reduced probability of disease severity, hospital admission rate, early recovery from illness, and mortality. Asian J. Med. Biol. Res. 2022, 8 (4), 251-263

Background: COVID 19 era is continuing globally even one and half years of turning out and claiming lives and startled with newly emerged variants. Many studies regarding COVID 19 treatment were published but some options were beneficiary in early stage and later were contradictory to apply it, making clinicians to dim. So this study was carried out reveal potential efficacy of commonly prescribed regimen in COVID unit. Materials and methods: This observational study conducted in three dedicated COVID hospital in Chattogram, Bangladesh. Total 209 cases with RT-PCR positive and symptomatic cases with RT-PCR negative subjects were enrolled in this study. Results: Half of the patients 53% (n=111) who got antiviral remdisivir, 53.6% n=103 were improved, 46.7% n=7 was died and p value < 0.01,comparing to 28.2% (n=59) got favipiravir in whom, 27.6% n=53 were improved, 40% n=6 was died. 16.3% (n=34) patient got Tocilizumab, in whom 73.52% n=25 were improved, 23.52% n=8 was died. 8.6% (n=18) got convalescent plasma in whom 6.3% n=12 was improved, 40% n=6 was died and p value was significant. Those who were given both Tocilizumab and Remdisivir, 76.9% n=20 were improved and 19.2% n=5 were died in comparison to patient treated with Remdisivir only 97.6% n=83 were improved and 2.3% n-2 were died. Conclusion: Even after 18 months of starting COVID, only established treatment options are oxygen and dexamethasone. As data about efficacy of antiviral and others are so changing according to COVID variants and different country. So emphasize should be about prevention and avoiding injudicious use of anti COVID medications. IAHS Medical Journal Vol 5(1), June 2022; 56-59

not available Chatt Maa Shi Hosp Med Coll J; Vol.21 (2); July 2022; Page 1-2

Background COVID 19 pandemic had taken away lots of human life prematurely worldwide and death laid its icy hands also on Bangladesh. So, objectives of this study were to review the death cases in terms of monthly distributions, age, sex, co-morbidities, localities and duration of hospital due to the COVID 19 infection. Results There was a low frequency of death in the months May-2021 and October-2021(7.1% and 2.7% respectively) but more during June − 2021 to September 2021 (12.4%, 16.8%, 42.5% and 18.6% respectively). Female deaths were more than male deaths(53.1% vs 46.9%, p

not available Chatt Maa Shi Hosp Med Coll J; Vol.21 (1); January 2022; Page 1-2